http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 16:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Corvese+Brian/26591547.html si-local-file:///var/storage/secattach/20260602/26591547.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Corvese+Brian/26591547.html Tue, 02 Jun 2026 16:06:00 -0400 INKT O.53188883 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Corvese+Brian/26591547.html si-local-file:///var/storage/secattach/20260602/26591547.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Corvese+Brian/26591547.html Tue, 02 Jun 2026 16:06:00 -0400 INKT O.53188883 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Ryan+Barbara/26591561.html si-local-file:///var/storage/secattach/20260602/26591561.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Ryan+Barbara/26591561.html Tue, 02 Jun 2026 16:06:00 -0400 INKT O.53188883 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Ryan+Barbara/26591561.html si-local-file:///var/storage/secattach/20260602/26591561.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Ryan+Barbara/26591561.html Tue, 02 Jun 2026 16:06:00 -0400 INKT O.53188883 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Holcomb+John+Bradley/26591568.html si-local-file:///var/storage/secattach/20260602/26591568.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Holcomb+John+Bradley/26591568.html Tue, 02 Jun 2026 16:06:00 -0400 INKT O.53188883 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Holcomb+John+Bradley/26591568.html si-local-file:///var/storage/secattach/20260602/26591568.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Holcomb+John+Bradley/26591568.html Tue, 02 Jun 2026 16:06:00 -0400 INKT O.53188883 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+WIINBERG+ULF/26591522.html si-local-file:///var/storage/secattach/20260602/26591522.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+WIINBERG+ULF/26591522.html Tue, 02 Jun 2026 16:05:00 -0400 INKT O.53188883 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+WIINBERG+ULF/26591522.html si-local-file:///var/storage/secattach/20260602/26591522.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+WIINBERG+ULF/26591522.html Tue, 02 Jun 2026 16:05:00 -0400 INKT O.53188883 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Behner+Peter/26591541.html si-local-file:///var/storage/secattach/20260602/26591541.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Behner+Peter/26591541.html Tue, 02 Jun 2026 16:05:00 -0400 INKT O.53188883 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Behner+Peter/26591541.html si-local-file:///var/storage/secattach/20260602/26591541.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MiNK+Therapeutics%2C+Inc.+++For%3A+Mar+02++Filed+by%3A+Behner+Peter/26591541.html Tue, 02 Jun 2026 16:05:00 -0400 INKT O.53188883 http://www.streetinsider.com/FDA/MiNK+Therapeutics+doses+first+patient+in+phase+2+lung+injury+trial/26562324.html <p>MiNK Therapeutics (NASDAQ: INKT) announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 for acute lung injury and critical illness.</p> <p>The patient was dosed at First Lviv Territorial Medical Union in Lviv, Ukraine, following approval from Ukraine's Ministry of Health. The trial, designated C-1300-02, compares agenT-797 plus standard care against placebo plus standard care in patients with acute lung injury meeting Global Acute Respiratory Distress Syndrome criteria.</p> <p>The study evaluates intensive care unit outcomes including survival, ventilator-free days, ICU recovery, and biological measures related to treatment activity and immune function. The company expects preliminary http://www.streetinsider.com/FDA/MiNK+Therapeutics+doses+first+patient+in+phase+2+lung+injury+trial/26562324.html Thu, 28 May 2026 09:05:03 -0400 A.50200380 INKT O.38029282 O.53188883 http://www.streetinsider.com/FDA/MiNK+Therapeutics+doses+first+patient+in+phase+2+lung+injury+trial/26562324.html <p>MiNK Therapeutics (NASDAQ: INKT) announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 for acute lung injury and critical illness.</p> <p>The patient was dosed at First Lviv Territorial Medical Union in Lviv, Ukraine, following approval from Ukraine's Ministry of Health. The trial, designated C-1300-02, compares agenT-797 plus standard care against placebo plus standard care in patients with acute lung injury meeting Global Acute Respiratory Distress Syndrome criteria.</p> <p>The study evaluates intensive care unit outcomes including survival, ventilator-free days, ICU recovery, and biological measures related to treatment activity and immune function. The company expects preliminary http://www.streetinsider.com/FDA/MiNK+Therapeutics+doses+first+patient+in+phase+2+lung+injury+trial/26562324.html Thu, 28 May 2026 09:05:03 -0400 A.50200380 INKT O.38029282 O.53188883 http://www.streetinsider.com/FDA/MiNK+Therapeutics+doses+first+patient+in+phase+2+lung+injury+trial/26562324.html <p>MiNK Therapeutics (NASDAQ: INKT) announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 for acute lung injury and critical illness.</p> <p>The patient was dosed at First Lviv Territorial Medical Union in Lviv, Ukraine, following approval from Ukraine's Ministry of Health. The trial, designated C-1300-02, compares agenT-797 plus standard care against placebo plus standard care in patients with acute lung injury meeting Global Acute Respiratory Distress Syndrome criteria.</p> <p>The study evaluates intensive care unit outcomes including survival, ventilator-free days, ICU recovery, and biological measures related to treatment activity and immune function. The company expects preliminary http://www.streetinsider.com/FDA/MiNK+Therapeutics+doses+first+patient+in+phase+2+lung+injury+trial/26562324.html Thu, 28 May 2026 09:05:03 -0400 A.50200380 INKT O.38029282 O.53188883 http://www.streetinsider.com/FDA/MiNK+Therapeutics+doses+first+patient+in+phase+2+lung+injury+trial/26562324.html <p>MiNK Therapeutics (NASDAQ: INKT) announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 for acute lung injury and critical illness.</p> <p>The patient was dosed at First Lviv Territorial Medical Union in Lviv, Ukraine, following approval from Ukraine's Ministry of Health. The trial, designated C-1300-02, compares agenT-797 plus standard care against placebo plus standard care in patients with acute lung injury meeting Global Acute Respiratory Distress Syndrome criteria.</p> <p>The study evaluates intensive care unit outcomes including survival, ventilator-free days, ICU recovery, and biological measures related to treatment activity and immune function. The company expects preliminary http://www.streetinsider.com/FDA/MiNK+Therapeutics+doses+first+patient+in+phase+2+lung+injury+trial/26562324.html Thu, 28 May 2026 09:05:03 -0400 A.50200380 INKT O.38029282 O.53188883 http://www.streetinsider.com/Press+Releases/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html <ul type="disc"><li style="margin-top:4pt; margin-bottom:8pt;"><em>First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Landmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing therapies</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Preliminary data expected in the second half of 2026</em></li></ul> <p>NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BpxtMJBkReNegAiN6gJGuFzX7JpY6RkbDQku3TGn-cvPh-x4YHn_83groXgoaZKwuLff9iCxB6Kaw97z9m0JXQHzd2WNmXMY8vEvhyz0cn0=" rel="nofollow" target="_blank">MiNK Therapeutics</a> (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been http://www.streetinsider.com/Press+Releases/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html Thu, 28 May 2026 09:04:00 -0400 A.50200380 INKT O.38029282 O.53188883 http://www.streetinsider.com/Press+Releases/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html <ul type="disc"><li style="margin-top:4pt; margin-bottom:8pt;"><em>First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Landmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing therapies</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Preliminary data expected in the second half of 2026</em></li></ul> <p>NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BpxtMJBkReNegAiN6gJGuFzX7JpY6RkbDQku3TGn-cvPh-x4YHn_83groXgoaZKwuLff9iCxB6Kaw97z9m0JXQHzd2WNmXMY8vEvhyz0cn0=" rel="nofollow" target="_blank">MiNK Therapeutics</a> (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been http://www.streetinsider.com/Press+Releases/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html Thu, 28 May 2026 09:04:00 -0400 A.50200380 INKT O.38029282 O.53188883 http://www.streetinsider.com/Press+Releases/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html <ul type="disc"><li style="margin-top:4pt; margin-bottom:8pt;"><em>First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Landmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing therapies</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Preliminary data expected in the second half of 2026</em></li></ul> <p>NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BpxtMJBkReNegAiN6gJGuFzX7JpY6RkbDQku3TGn-cvPh-x4YHn_83groXgoaZKwuLff9iCxB6Kaw97z9m0JXQHzd2WNmXMY8vEvhyz0cn0=" rel="nofollow" target="_blank">MiNK Therapeutics</a> (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been http://www.streetinsider.com/Press+Releases/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html Thu, 28 May 2026 09:04:00 -0400 A.50200380 INKT O.38029282 O.53188883 http://www.streetinsider.com/Press+Releases/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html <ul type="disc"><li style="margin-top:4pt; margin-bottom:8pt;"><em>First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Landmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing therapies</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Preliminary data expected in the second half of 2026</em></li></ul> <p>NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BpxtMJBkReNegAiN6gJGuFzX7JpY6RkbDQku3TGn-cvPh-x4YHn_83groXgoaZKwuLff9iCxB6Kaw97z9m0JXQHzd2WNmXMY8vEvhyz0cn0=" rel="nofollow" target="_blank">MiNK Therapeutics</a> (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been http://www.streetinsider.com/Press+Releases/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html Thu, 28 May 2026 09:04:00 -0400 A.50200380 INKT O.38029282 O.53188883 http://www.streetinsider.com/Globe+Newswire/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html <ul type="disc"><li style="margin-top:4pt; margin-bottom:8pt;"><em>First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Landmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing therapies</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Preliminary data expected in the second half of 2026</em></li></ul> <p>NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BpxtMJBkReNegAiN6gJGuFzX7JpY6RkbDQku3TGn-cvPh-x4YHn_83groXgoaZKwuLff9iCxB6Kaw97z9m0JXQHzd2WNmXMY8vEvhyz0cn0=" rel="nofollow" target="_blank">MiNK Therapeutics</a> (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been http://www.streetinsider.com/Globe+Newswire/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html Thu, 28 May 2026 09:04:00 -0400 A.50200380 INKT O.38029282 O.53188883 http://www.streetinsider.com/Globe+Newswire/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html <ul type="disc"><li style="margin-top:4pt; margin-bottom:8pt;"><em>First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Landmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing therapies</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Preliminary data expected in the second half of 2026</em></li></ul> <p>NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BpxtMJBkReNegAiN6gJGuFzX7JpY6RkbDQku3TGn-cvPh-x4YHn_83groXgoaZKwuLff9iCxB6Kaw97z9m0JXQHzd2WNmXMY8vEvhyz0cn0=" rel="nofollow" target="_blank">MiNK Therapeutics</a> (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been http://www.streetinsider.com/Globe+Newswire/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html Thu, 28 May 2026 09:04:00 -0400 A.50200380 INKT O.38029282 O.53188883 http://www.streetinsider.com/Globe+Newswire/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html <ul type="disc"><li style="margin-top:4pt; margin-bottom:8pt;"><em>First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Landmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing therapies</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Preliminary data expected in the second half of 2026</em></li></ul> <p>NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BpxtMJBkReNegAiN6gJGuFzX7JpY6RkbDQku3TGn-cvPh-x4YHn_83groXgoaZKwuLff9iCxB6Kaw97z9m0JXQHzd2WNmXMY8vEvhyz0cn0=" rel="nofollow" target="_blank">MiNK Therapeutics</a> (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been http://www.streetinsider.com/Globe+Newswire/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html Thu, 28 May 2026 09:04:00 -0400 A.50200380 INKT O.38029282 O.53188883 http://www.streetinsider.com/Globe+Newswire/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html <ul type="disc"><li style="margin-top:4pt; margin-bottom:8pt;"><em>First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Landmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing therapies</em></li><li style="margin-top:4pt; margin-bottom:8pt;"><em>Preliminary data expected in the second half of 2026</em></li></ul> <p>NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BpxtMJBkReNegAiN6gJGuFzX7JpY6RkbDQku3TGn-cvPh-x4YHn_83groXgoaZKwuLff9iCxB6Kaw97z9m0JXQHzd2WNmXMY8vEvhyz0cn0=" rel="nofollow" target="_blank">MiNK Therapeutics</a> (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been http://www.streetinsider.com/Globe+Newswire/MiNK+Therapeutics+Announces+First+Patient+Dosed+in+Randomized+Phase+2+Trial+of+agenT-797+in+Acute+Lung+Injury+and+Critical+Illness/26562316.html Thu, 28 May 2026 09:04:00 -0400 A.50200380 INKT O.38029282 O.53188883 http://www.streetinsider.com/Corporate+News/Agenus+reports+AI+analysis+shows+improved+response+rates+for+cancer+treatment/26536499.html <p>Agenus Inc. (NASDAQ: AGEN) announced retrospective data showing that artificial intelligence analysis of routine tumor images identified patients more likely to respond to its experimental cancer treatment combination.</p><p>The analysis used Noetik's TARIO-2 platform to examine standard pathology images from 113 patients treated with botensilimab plus balstilimab in a Phase 1b trial. The AI system analyzed spatial tumor microenvironment patterns from hematoxylin and eosin stained tissue samples taken before treatment.</p><p>In patients with microsatellite stable metastatic colorectal cancer without active liver metastases, the AI-identified subgroup showed a 64% response rate compared to 9% in the remaining patients. The AI-identified group also demonstrated http://www.streetinsider.com/Corporate+News/Agenus+reports+AI+analysis+shows+improved+response+rates+for+cancer+treatment/26536499.html Thu, 21 May 2026 17:00:46 -0400 AGEN INKT http://www.streetinsider.com/Corporate+News/Agenus+reports+AI+analysis+shows+improved+response+rates+for+cancer+treatment/26536499.html <p>Agenus Inc. (NASDAQ: AGEN) announced retrospective data showing that artificial intelligence analysis of routine tumor images identified patients more likely to respond to its experimental cancer treatment combination.</p><p>The analysis used Noetik's TARIO-2 platform to examine standard pathology images from 113 patients treated with botensilimab plus balstilimab in a Phase 1b trial. The AI system analyzed spatial tumor microenvironment patterns from hematoxylin and eosin stained tissue samples taken before treatment.</p><p>In patients with microsatellite stable metastatic colorectal cancer without active liver metastases, the AI-identified subgroup showed a 64% response rate compared to 9% in the remaining patients. The AI-identified group also demonstrated http://www.streetinsider.com/Corporate+News/Agenus+reports+AI+analysis+shows+improved+response+rates+for+cancer+treatment/26536499.html Thu, 21 May 2026 17:00:46 -0400 AGEN INKT http://www.streetinsider.com/FDA/Agenus+reports+AI+analysis+shows+improved+response+rates+for+cancer+treatment/26536499.html <p>Agenus Inc. (NASDAQ: AGEN) announced retrospective data showing that artificial intelligence analysis of routine tumor images identified patients more likely to respond to its experimental cancer treatment combination.</p><p>The analysis used Noetik's TARIO-2 platform to examine standard pathology images from 113 patients treated with botensilimab plus balstilimab in a Phase 1b trial. The AI system analyzed spatial tumor microenvironment patterns from hematoxylin and eosin stained tissue samples taken before treatment.</p><p>In patients with microsatellite stable metastatic colorectal cancer without active liver metastases, the AI-identified subgroup showed a 64% response rate compared to 9% in the remaining patients. The AI-identified group also demonstrated http://www.streetinsider.com/FDA/Agenus+reports+AI+analysis+shows+improved+response+rates+for+cancer+treatment/26536499.html Thu, 21 May 2026 17:00:46 -0400 AGEN INKT